Sign In
Buy FLGT
$16.55
-3.66 (-18.11%)
At Close: Jul 31, 2026
Fulgent to Announce First Quarter 2025 Financial Results on Friday, May 2, 2025
04:05pm, Thursday, 10'th Apr 2025
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a the
Stock Picks From Seeking Alpha's March 2025 New Analysts
02:30pm, Friday, 04'th Apr 2025
In March, we welcomed 30 new analysts to Seeking Alpha, and in this article we are showcasing their stock picks and investment strategies. Our analysts covered a diverse set of industries—including
Fulgent Genetics: Undervalued, CFO Buying, And Promising Drug Candidates Make It A Buy
05:46am, Thursday, 20'th Mar 2025
CFO bought 1.5 million worth on March 5th, a Price/Book ratio of 0.43x and a Net Current Assets Value (NCAV) of 0.68x that day. Now it's trading at 0.47x Price/Book Value and 0.72x NCAV, showing a sig
Fulgent Genetics, Inc. (FLGT) Q4 2024 Earnings Conference Call Transcript
11:57am, Friday, 28'th Feb 2025
Fulgent Genetics, Inc. (NASDAQ:FLGT ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Melanie Solomon - IR Ming Hsieh - Chairman and CEO Brandon Perthuis - Chief Com
Fulgent Genetics Revenue Tops Estimates
10:44am, Friday, 28'th Feb 2025
Laboratory services and therapeutic development specialist Fulgent Genetics (FLGT 0.53%) delivered a standout performance in the fourth quarter, topping analysts' consensus estimates. On Friday, Feb.
Fulgent Genetics, Inc. (FLGT) Q4 Earnings and Revenues Beat Estimates
09:10am, Friday, 28'th Feb 2025
Fulgent Genetics, Inc. (FLGT) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.12 per share. This compares to earnings of $0.28 per share a yea
Fulgent Reports Fourth Quarter and Full Year 2024 Financial Results
07:00am, Friday, 28'th Feb 2025
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a th
Fulgent to Announce Fourth Quarter and Full Year 2024 Financial Results on Friday, February 28, 2025
04:05pm, Thursday, 06'th Feb 2025
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a the
BOSTON & EL MONTE, Calif.--(BUSINESS WIRE)--Foundation Medicine to launch two new hereditary germline tests in the United States through a partnership with Fulgent Genetics.
Fulgent Genetics: High Insider Ownership Supports Asymmetric Upside
01:25am, Tuesday, 24'th Dec 2024
Fulgent Genetics: High Insider Ownership Supports Asymmetric Upside
Wall Street Analysts Predict a 31.06% Upside in Fulgent Genetics (FLGT): Here's What You Should Know
10:56am, Monday, 09'th Dec 2024
The mean of analysts' price targets for Fulgent Genetics (FLGT) points to a 31.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among
All You Need to Know About Fulgent Genetics (FLGT) Rating Upgrade to Strong Buy
01:00pm, Friday, 22'nd Nov 2024
Fulgent Genetics (FLGT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
New Strong Buy Stocks for November 22nd
07:05am, Friday, 22'nd Nov 2024
SNEX, PKG, APAM, MNDY and FLGT have been added to the Zacks Rank #1 (Strong Buy) List on November 22, 2024.
Fulgent Genetics, Inc. (FLGT) Q3 2024 Earnings Call Transcript
02:07am, Monday, 11'th Nov 2024
Fulgent Genetics, Inc. (NASDAQ:FLGT ) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET Company Participants Melanie Solomon - Investor Relations Ming Hsieh - Chairman, Chief Executive Offi
Fulgent Genetics, Inc. (FLGT) Surpasses Q3 Earnings and Revenue Estimates
09:15am, Friday, 08'th Nov 2024
Fulgent Genetics, Inc. (FLGT) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of a loss of $0.19 per share. This compares to loss of $0.39 per share a year ag
